# Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Lo

Source: https://onco.cc/trials/nct07151586/  
OnCo record `nct07151586` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan and trastuzumab deruxtecan in triple-negative breast cancer, run by UNICANCER, not yet recruiting.

## Summary

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT07151586 by UNICANCER, with a registry enrolment figure of 260 participants, started 2026-09 and due to reach its primary completion in 2029-10. Interventions recorded: Sacituzumab Govitecan / Trastuzumab Deruxtecan. Conditions listed: Triple Negative Breast Neoplasms; Neoplasm Metastasis; HER 2 Low-expressing Breast Cancer. Triple-negative eligibility wording from the registry: "* Histologically confirmed metastatic or locally advanced and unresectable triple-negative breast cancer, meeting both of the following criteria by local testing:". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: ALTER
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07151586
- Phase: 2
- Setting: A Phase 2, Multicenter, Randomized, Open-label Trial Assessing Sacituzumab-govitecan and Trastuzumab-deruxtecan Combinations in an Alternating Regimen for Patients With Metastatic or Locally Advanced HER2-low Triple-negative Breast Cancer
- Sponsor: UNICANCER
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT07151586: https://clinicaltrials.gov/study/NCT07151586

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07151586.json